Latest News
Genflow Biosciences receives first EUR336,467 tranche of EUR4m Wallonia grant
2 March 2026 - European-based biotechnology company Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) announced on Monday that it has received the first instalment of EUR336,467 from a previously announced EUR4m non-dilutive grant awarded by the Wal...
Novacyt completes acquisition of Southern Cross Diagnostics
2 March 2026 - Molecular diagnostics company Novacyt S.A. (EURONEXT GROWTH: ALNOV) (AIM: NCYT) announced on Monday that, further to its 23 February 2026 notification, its wholly owned subsidiary, Novacyt Holdings UK Limited, has completed the acquisi...
Eli Lilly's Olumiant (baricitinib) receives positive European regulatory opinion for approval to treat adolescents with severe alopecia areata
2 March 2026 - Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Friday announced a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Olumiant (baricitinib) for the tre...
Blue Earth Diagnostics reports positive results from comparator study of POSLUMA (flotufolastat F 18) and piflufolastat F 18 urinary bladder radioactivity
2 March 2026 - UK-based Blue Earth Diagnostics, a Bracco Group company focused on the development and commercialisation of innovative positron emission tomography (PET) radiopharmaceuticals, on Friday announced results from the first head-to-head stu...
Atrium Therapeutics launches as newly independent, publicly traded company
2 March 2026 - Atrium Therapeutics Inc (Nasdaq:RNA) announced on Friday that it has launched as a newly independent, publicly traded company focused on delivering RNA therapeutics directly to the heart to transform care for people living with rare, l...